Skip to main content

and
  1. Article

    Open Access

    Ripretinib versus sunitinib in gastrointestinal stromal tumor: ctDNA biomarker analysis of the phase 3 INTRIGUE trial

    INTRIGUE was an open-label, phase 3 study in adult patients with advanced gastrointestinal stromal tumor who had disease progression on or intolerance to imatinib and who were randomized to once-daily ripretin...

    Michael C. Heinrich, Robin L. Jones, Suzanne George, Hans Gelderblom in Nature Medicine (2024)